33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • MAIT and Vδ2 unconventional T cells predict favorable outcome after allogeneic HCT and are supported by a diverse intestinal microbiome
    Meeting Abstract

    Andrlova, H.; Miltiadous, O.; Dai, A.; Gardner, R.; El Daker, S.; Slingerland, J. B.; Giardina, P. A.; Clurman, A.; Gomes, A. L. C.; Nguyen, C. L.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A first-in-human phase 1 study of oral LOXO-338, a selective BCL2 inhibitor, in patients with advanced hematologic malignancies (Trial in progress)
    Meeting Abstract

    Alencar, A. J.; Roeker, L. E.; Hoffman, M.; Murthy, G. S. G.; Patel, V.; Ku, N. C.; Pauff, J. M.; Eyre, T. A.; Jurczak, W.; Le Gouill, S.
    Blood (2021)

    Fulltext@MSK | Save
  • Trial in progress: Asciminib in monotherapy 4 CML (AIM4CML), a phase IIIb study of asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without or with T315I mutations
    Meeting Abstract

    Andorsky, D.; Tomassetti, S.; Deutsch, Y. E.; Broun, E. R.; Issa, G. C.; Levy, M. Y.; Deininger, M. W.; Maegawa, R.; Shrestha, A.; Mauro, M. J.
    Blood (2021)

    Fulltext@MSK | Save
  • Phase 1/2 study of NEXI-001 donor-derived multi-antigen specific CD8+ T cells for the treatment of relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic transplantation
    Meeting Abstract

    Al Malki, M. M.; Vasu, S.; Modi, D.; Perales, M. A.; Ghoda, L. Y.; Bui, D.; Edavana, V.; Lu, E.; Kim, S.; Suarez, L.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Germline RUNX1 mutations induce inflammation in hematopoietic stem and progenitor cells and predispose to hematologic malignancies
    Meeting Abstract

    Ahmad, M. H.; Hegde, M.; Wong, W. J.; Dunbar, A.; Carrascoso, A.; Garett, L. J.; Ferreira, N. K.; Liu, H.; Li, R.; Eberg, B. L.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase 2 study of dasatinib, prednisone, and blinatumomab for older patients with philadelphia-chromosome (Ph) positive or Ph-like acute lymphoblastic leukemia (ALL) (with dasatinib sensitive fusions/ mutations)
    Meeting Abstract

    Advani, A.; Moseley, A.; O'Dwyer, K.; Wood, B.; Park, J. H.; Wieduwilt, M.; Jeyakumar, D.; Yaghmour, G.; Atallah, E. L.; Gerds, A. T.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • JSP191 As a single-agent conditioning regimen results in successful engraftment, donor myeloid chimerism, and production of donor derived naive lymphocytes in patients with severe combined immunodeficiency (SCID)
    Meeting Abstract

    Agarwa, R.; Dvorak, C. C.; Prockop, S.; Kwon, H. S.; Long-Boyle, J. R.; Le, A.; Brown, J. W.; Merkel, E.; Truong, K.; Velasco, B.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Two-year follow-up of transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R/R) large B-cell lymphomas (LBCL)
    Meeting Abstract

    Abramson, J. S.; Palomba, M. L.; Gordon, L. I.; Lunning, M. A.; Wang, M.; Arnason, J. E.; Purev, E.; Maloney, D. G.; Andreadis, C.; Sehgal, A. R.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Targeting serine synthesis in brain metastasis
    Meeting Abstract

    Ngo, B.; Kim, E.; Osorio-Vasquez, V.; Doll, S.; Bustraan, S.; Liang, R.; Luengo, A.; Davidson, S.; Ali, A.; Ferraro, G.; more...
    Neuro-Oncology Advances (2021)

    Fulltext@MSK | Save
  • Intracranial activity of tepotinib in patients with MET exon 14 (METex14) skipping NSCLC enrolled in VISION
    Meeting Abstract

    Bestvina, C. M.; Le, X.; Veillon, R.; Anderson, I.; Patel, J.; Demedts, I.; Garassino, M.; Mazières, J.; Morise, M.; Smit, E.; more...
    Neuro-Oncology Advances (2021)

    Fulltext@MSK | Save